Is dupixent safe for patients with a history of cancer?

Is dupixent safe for patients with a history of cancer?

Current prescribing information does not list prior cancer as a contraindication, and the drug has no boxed warning for malignancy.

Does dupixent increase cancer risk?

Dupixent blocks IL-4 and IL-13 signaling. These cytokines can suppress some tumors, but they also drive allergic inflammation. No clinical study has shown an increase in new cancers among treated patients, yet long-term data are still limited.

How long have patients with past cancer been followed?

Most trials excluded people with active or recent malignancy. Post-marketing surveillance has not identified a clear signal so far, but the largest cohort followed for more than five years remains modest.

What does the FDA label say?

The label notes that patients with a history of cancer were not studied extensively and recommends weighing individual benefit versus risk.

When does the dupixent patent expire?

The key U.S. composition-of-matter patent expires in 2031, with possible pediatric exclusivity extending protection into 2032.

Are biosimilars already in development?

Several companies have announced dupixent biosimilar programs, but none have reached late-stage trials yet.

How do doctors usually decide?

Oncologists and allergists often review the original cancer type, stage, and time since remission. If the patient has been cancer-free for five or more years, many proceed with dupixent while scheduling closer skin and lymph-node checks.